Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

i-Sens

Develops and manufactures self monitoring blood glucose test systems, including POCT diagnostic devices such as blood... read more Featured Products: More products

Download Mobile App





i-SENS Showcasing Point-of-Care Diagnostics and Glucose Monitoring

By LabMedica International staff writers
Posted on 16 Nov 2026

i-SENS (Seoul, South Korea) showcases its in vitro diagnostic (IVD) systems and diabetes management technologies at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. More...

The company presents a range of point-of-care analyzers, continuous glucose monitoring (CGM) systems, and connected diabetes care solutions designed to support diagnostic testing across hospital laboratories and near-patient settings.

Among the products on display are the i-SmartCare 10 blood gas analyzer and i-Smart 30 Pro electrolyte analyzer. These systems are designed to support clinical testing in healthcare environments where timely diagnostic results are important. The company also presents additional point-of-care analyzers, highlighting its broader portfolio of diagnostic technologies for decentralized testing.

The i-SmartCare 10 provides blood gas analysis for clinical applications, while the i-Smart 30 Pro supports electrolyte testing. Both instruments form part of i-SENS' IVD portfolio, which also includes clinical chemistry and immunoassay analyzers. The systems are intended to address diagnostic requirements across different clinical settings, from centralized laboratories to locations closer to patients.

In addition to its laboratory diagnostics portfolio, i-SENS features CareSens Air 2, its next-generation continuous glucose monitoring system. The company also displays the existing CareSens Air platform, which provides real-time glucose measurements and trend information to support diabetes management. These technologies are designed to help users monitor glucose levels and track changes over time.

The diabetes care portfolio also includes Sens365, a digital platform for glucose data management and sharing. The system enables glucose monitoring information to be organized and accessed by healthcare providers, supporting ongoing diabetes management. Visitors can also explore the company's range of CareSens blood glucose monitoring systems for routine testing.

The exhibition highlights i-SENS' focus on integrating diagnostic testing with digital health technologies. By combining point-of-care analyzers, continuous glucose monitoring, and data management platforms, the company aims to support more connected diagnostic workflows and improve access to clinical information across different healthcare environments.

i-SENS exhibits at Booth B51 in Hall 3, where visitors can examine its diagnostic and diabetes care technologies and discuss potential collaborations. The company uses its participation at MEDICA 2026 to engage with healthcare professionals and distribution partners as it continues to expand its international diagnostics business.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.